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Abstract
Background: There is increasing recognition that pulmonary artery stiffness is an important determinant of right ventricular
(RV) afterload in pulmonary arterial hypertension (PAH). We used intravascular ultrasound (IVUS) to evaluate the mechanical
properties of the elastic pulmonary arteries (PA) in subjects with PAH, and assessed the effects of PAH-specific therapy on
indices of arterial stiffness.
Method: Using IVUS and simultaneous right heart catheterisation, 20 pulmonary segments in 8 PAH subjects and 12
pulmonary segments in 8 controls were studied to determine their compliance, distensibility, elastic modulus and stiffness
index b. PAH subjects underwent repeat IVUS examinations after 6-months of bosentan therapy.
Results: At baseline, PAH subjects demonstrated greater stiffness in all measured indices compared to controls: compliance
(1.5060.11610
–2 mm
2/mmHg vs 4.4960.43610
–2 mm
2/mmHg, p,0.0001), distensibility (0.3260.03%/mmHg vs
1.1860.13%/mmHg, p,0.0001), elastic modulus (720664 mmHg vs 198619 mmHg, p,0.0001), and stiffness index b
(15.061.4 vs 11.060.7, p=0.046). Strong inverse exponential associations existed between mean pulmonary artery pressure
and compliance (r
2=0.82, p,0.0001), and also between mean PAP and distensibility (r
2=0.79, p=0.002). Bosentan therapy,
for 6-months, was not associated with any significant changes in all indices of PA stiffness.
Conclusion: Increased stiffness occurs in the proximal elastic PA in patients with PAH and contributes to the pathogenesis
RV failure. Bosentan therapy may not be effective at improving PA stiffness.
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Introduction
Pulmonary arterial hypertension (PAH) is a group of conditions
characterised by similar pathophysiological changes in the pulmonary
vascular bed, resulting in pre-capillary pulmonary hypertension,
increased right ventricular (RV) afterload and ultimately RV failure.[1]
The classical arteriopathy described in PAH involves the distal
muscular arteries and arterioles, which are generally regarded as
resistance vessels. Endothelial dysfunction, imbalance between vaso-
constrictor and vasodilator substances, and smooth muscle prolifera-
tion lead to vessel remodeling, loss of vessel cross sectional area, and a
progressive rise in pulmonary vascular resistance (PVR).[2]
In clinical practice, RV afterload is often described in terms of
PVR but this is only a measure of steady pulmonary pressure-flow
relationship and neglects the pulsatile nature of blood flow in any
circulation.[3] Thus, assessment of arterial compliance (or its
conceptual inverse of arterial stiffness) enables the pulsatile
component of RV afterload to be taken into account.[4] In fact,
global arterial compliance of the pulmonary circulation and local
stiffness of the proximal pulmonary artery have both been shown
to be predictors of mortality in PAH from recent studies.[5,6,7]
The proximal elastic pulmonary arteries (PA) function as conduit
vessels to buffer the pulsatile arterial load and distribute blood flow
to the peripheral circulation. Post-mortem histological studies have
demonstrated morphological changes in the elastic PA in subjects
with PAH.[8] Furthermore, recent animal and human studies using
frequency domain impedance analysis have enhanced our under-
standing of the important contribution of proximal PA stiffness to
the pathogenesis of RV failure. [9,10,11,12]
Intravascular ultrasound (IVUS) allows real-time imaging of the
morphology and function of the pulmonary vasculature when
performed with simultaneous hemodynamic monitoring. It can
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opposed to global changes affecting the entire circulation. To date,
only few studies have characterised the mechanical properties of
the proximal elastic PA in patients with PAH using the IVUS
technique. [8,13,14,15]
Current PAH-specific therapies target the dysfunctional path-
ways implicated in disease pathogenesis and have predominantly
vasodilator effects on the pulmonary vasculature. Bosentan, a dual
endothelin receptor antagonist, has been shown to reverse arterial
remodeling in animal models of PAH, but its in vivo effects on
proximal PA stiffness and remodeling have not been studied in
humans. Therefore, we sought to use IVUS to determine the local
elastic properties of the proximal PA in patients with PAH, and
evaluate the effects of 6-months therapy with bosentan on arterial
stiffness.
Methods
Ethics Statement
The research was conducted according to the principles
expressed in the Declaration of Helsinki. The study was approved
by the local ethics committee and all subjects provided informed
consent.
Subjects
The study subjects consisted of a healthy control group (n=8)
and a PAH group (n=8). PAH subjects were assessed as part of a
6-month study that investigated the effect of bosentan therapy on
pulmonary endothelial function,[16] who underwent additional
IVUS imaging. Inclusion criteria for PAH subjects were diagnosis
with idiopathic or connective tissue disease related PAH, no prior
PAH-specific therapy, and NYHA Function Class III or IV
symptoms. All PAH subjects were prescribed bosentan, a dual
endothelin receptor antagonist, for clinical indications and
returned for follow-up IVUS assessment and right heart
catheterisation after 6-months of therapy. Bosentan was prescribed
at a dosage of 62.5 mg twice daily for the first month, followed by
125 mg twice daily. All subjects complied with this dosage
schedule. Age and sex matched control subjects were recruited
from the cardiac catheterisation laboratory, and underwent IVUS
imaging after documentation of normal pulmonary artery
hemodynamics invasively.
IVUS Imaging of Elastic Pulmonary Arteries
Right heart catheterisation was performed via the right femoral
vein approach. Right atrial, right ventricular and pulmonary
artery pressures were all measured at end-expiration. With
continuous hemodynamic monitoring, IVUS imaging of PA were
performed using a 40 MHz catheter (Atlantis SR Pro Imaging
Catheter, Boston Scientific, Natick, USA), which had an axial
resolution of 200 um. IVUS images were displayed by an image
console (HP Sonos 1000, Hewlett-Packard, Massachusetts, USA)
at a frame rate of 30/secs.
The IVUS catheter was advanced distally into a selected lobar
PA, followed by a pullback manoeuvre at a rate of 0.5 mm/sec. If
feasible and anatomically accessible, we attempted to image
multiple pulmonary lobes in each subject. Twenty-one pulmonary
lobes were imaged in PAH subjects; and 13 pulmonary lobes in
control subjects. Image quality was inadequate for analysis in one
lobe of a PAH subject and also in one lobe of a control subject.
Thus, a total of 20 pulmonary lobes from 8 PAH subjects were
included in the final analysis (four subjects had two lower lobes and
one upper lobe studied; two had one upper and one lower lobe
studied; and two had two lower lobes studied). For the controls, a
total of 12 pulmonary lobes from 8 subjects were included (three
had two lower lobes studied; three had one lower lobe studied; one
had one upper lobe studied; and one had upper and one lower
lobe studied).
Selective pulmonary angiography was performed to determine
the anatomical position of each imaged PA segment. On follow-up
studies, the same PA segments were imaged according to baseline
angiography. IVUS images were recorded and digitalised for off-
line analysis. The accuracy of IVUS-derived measurements of PA
diameter, luminal area and wall thickness has previously been
validated against in vitro anatomical measurements.[17,18,19]
IVUS-Derived Measurements of Pulmonary Artery Elastic
Properties
IVUS image analysis was performed by two study investigators
blinded to the clinical status and hemodynamics of subjects, using
a commercially available imaging software (Image J Ver 1.44,
NIH, USA). The baseline study was cued to the most distal, least-
branching segment of the PA with good image quality (defined as
complete circumferential demarcation of the intima and wall to
adventitia boundaries). The follow-up IVUS was then cued to a
point of equivalent PA diameter. Analyses of IVUS images were
averaged over 3 consecutive cardiac cycles. The luminal margin
PA were traced at end-systole (defined as T wave onset on ECG)
and end-diastole (defined as QRS onset on ECG) to determine the
end-systolic luminal area (As) and end-diastolic luminal area (Ad),
respectively. Vessel diameters in end-systole (Ds) and end diastole
(Dd) were derived from the equation; D=26!(A/p).
Using the IVUS-derived measurements and pulmonary hemo-
dynamic acquired at the same procedure (simultaneously), indices
of arterial stiffness were used to characterise the elastic properties
of PA. Compliance was defined as the absolute area change for a
given pressure change (compliance=(As–Ad)/pulse pressure);
distensibility was defined as the relative percentage area change
for a given pressure change (distensibility=(As–Ad)6100/pulse
pressure6Ad ), elastic modulus as the pressure change required for
a theoretical 100% increase in vessel diameter (elastic modulus=-
pulse pressure6Dd/[Ds–Dd]), and stiffness index b was calculated
by the formula (Stiffness Index b=ln(SPAP/DPAP)/[(Ds–Dd)/
Dd]).[20] Total vessel area was defined by the area circumscribed
by the elastic lamina; wall area was defined as the total vessel area
minus luminal area; and % wall thickness = wall area/total vessel
area6100 (Figure 1).
Statistical Analysis
Data are expressed as mean6SD unless otherwise stated.
Independent sample t-tests were used to compare baseline
differences between the control and PAH groups; and paired t-
tests were used to compare the effects of bosentan within the PAH
group. The association between mean pulmonary artery pressure
and stiffness indices were explored using regression analysis, and
different curve fitting models were tested and compared with
F and R
2 statistics. A two-sided p value ,0.05 was regarded as
significant. Analyses were performed on a biostatistics and
graphing software (Prism 5, Graphpad, California, USA).
Results
Baseline characteristics study populations
The age and gender of PAH subjects and control subjects were
well matched (6664 years vs. 6764 years; 5 females in each
group). In the PAH group (5 subjects with idiopathic PAH, 3 with
scleroderma-associated PAH), baseline hemodynamic revealed
severe pulmonary hypertension with a mean pulmonary artery
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pressure (PCWP) of 1063; and all subjects were in NYHA
functional class III. Control group had normal pulmonary
hemodynamic with mean PAP of 1662 mmHg and PCWP of
963 mmHg.
In Vivo assessment of pulmonary artery elastic properties
with IVUS
At baseline, the mean luminal diameters of PAs were similar in
PAH and control subjects (2.560.1 mm vs. 2.460.1 mmHg,
respectively; mean6SEM, p=0.89). PAH subjects demonstrated
increased % wall thickness compared to controls (3462% vs.
1762%; mean6SEM, p=0.001), as previously reported.[16]
Compared with controls, PAH subjects demonstrated reduced
compliance (1.5060.11610
-2 mm
2/mmHg vs 4.4960.43610
–
2 mm
2/mmHg; mean6SEM, p,0.0001), reduced distensibility
(0.3260.03%/mmHg vs 1.1860.13%/mmHg; mean6SEM,
p,0.0001), higher elastic modulus (720664 mmHg vs 1986
19 mmHg; mean6SEM, p,0.0001), and higher stiffness index b
(15.061.4 vs 11.060.7; mean6SEM, p=0.046) (Figure 2).
Of the 20 pulmonary lobes interrogated with IVUS in the PAH
group at baseline, only 14 lobes were able to be accessed
anatomically and studied at follow-up. If the results were analyzed
by consideration of only the 14 lobes that were measured before
and after bosentan, we still found a significant difference in all
stiffness indices between controls and PAH subjects at baseline.
Following 6-months of bosentan therapy, no significant
differences in all indices of PA stiffness were found in the PAH
group (Figure 3). Similarly, no significant change in % wall
thickness (3462% vs 3664%; mean6SEM, p=0.6) was ob-
served.
From the pooled data of all patients, non-linear regression fitted
best an inverse exponential relationship between mean PAP and
compliance (r
2=0.82, p,0.0001). Similarly, there was a strong
inverse exponential relationship between mean PAP and disten-
sibility (r
2=0.79, p=0.002) (Figure 4).
Discussion
The present study demonstrates that arterial stiffness is
significantly increased in the proximal elastic PA in patients with
PAH, and this increase in stiffness occurs in the setting of wall
thickening and vessel remodeling. This is also the first human
study to evaluate the effects of bosentan on local PA stiffness. We
did not observe any significant beneficial effects of bosentan on
arterial stiffness following 6-months of therapy.
Proximal PA involvement in PAH
PAH is regarded traditionally as a disease of the distal small
muscular arteries (,500 um in diameter).[21] Progressive obliter-
ation and remodeling of these distal ‘‘resistance’’ vessels eventually
lead to elevation in PVR and PAP.[22] The concept of PVR as a
determinant of RV afterload and prognosis in PAH has been well
studied. However, there is increasing recognition that a decrease
in arterial compliance (ie an increase in arterial stiffness) is of equal
importance in PAH. Therefore, an understanding of the changes
in arterial stiffness that occur in PAH is fundamental to the
understanding of progression to RV failure in this condition.
Furthermore, it is estimated that about 25% of the total
(pulsatile+steady) RV hydraulic load is composed of the pulsatile
component, a situation very different to the systemic circulation
where it is approximately 10%.[23]
In health, the proximal elastic PA are conduit vessels and
function as high capacitance tubes to deliver blood to the
peripheral microcirculation. Arterial compliance is most easily
and commonly determined by the ratio of the stroke volume to
pulse pressure, which describes the compliance of the entire
pulmonary circulation. Although useful, this measurement fails to
describe regional or local changes in arterial structure and
function. Our study, using in vivo imaging with IVUS, allowed
comprehensive assessment of regional arterial properties and
demonstrated that all indices of arterial stiffness are abnormal in
the proximal elastic PA in PAH subjects.
The increase in % wall thickness, compared to healthy controls,
suggests that these vessels have undergone significant remodeling,
and this process of remodeling explains, in part, the increase in
arterial stiffness. Stiffness index b has been used as an index of
arterial stiffness that is less pressure dependent compared to other
commonly used stiffness indices, as the logarithmic transformation
adjusts for the non-linear relationship between arterial elasticity
and luminal distending pressure.[24,25] Thus, the increase in
stiffness index b observed in PAH subjects supports an intrinsic
change in the elastic properties of the PA, as opposed to the sole
effect of increased distending pressure per se. Since the proximal
Figure 1. Representative images of an elastic PA with IVUS catheter in situ (white circle). Left image, IVUS image from a control subject
with normal wall thickness, as shown by the area bounded by the luminal margin (yellow circle) and the bright elastic lamina (white arrow). Right
image, IVUS image from a subject with severe PAH demonstrating a marked increase in wall thickness. Total vessel area was defined by the area
circumscribed by the bright elastic lamina; wall area was defined as the total vessel area minus luminal area; and % wall thickness = wall area/total
vessel area6100.
doi:10.1371/journal.pone.0033331.g001
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compliance of the pulmonary circulation, our findings indicate
that proximal PA stiffening in PAH is an important contributor to
the total RV afterload. Our study is in agreement with recent
magnetic resonance imaging (MRI) work in humans that has also
shown increased proximal PA stiffness in PAH[7,26,27,28,29], but
a key limitation of MRI studies is the lack of simultaneous
pulmonary artery pressure measurements to enable detailed
analyses arterial stiffness properties.
Relationship between PA stiffness and PA pressure
The compliance and distensibility data in our subjects demon-
strated strong inverse exponential associations with PA pressure.
Similar associations were also found by Sanz et al[26] using MRI
evaluation of the main PA and hemodynamic data derived from
same-day right heart catheterisation. The corollary of this relation-
ship is that at high PAP (such as in subjects with advanced PAH),
changes in PAP result in minimal changes in arterial compliance and
distensibility. In converse, along the ‘‘normal’’ ranges of PAP
(,25 mmHg), small changes in pressure are associated with
disproportionately large changes in compliance and distensibility.
Thus, as pulmonary vascular disease develops and PAP rises, most of
the fall in compliance and distensibility occurs at relatively low PAP.
On the other hand. compliance and distensibility reaches a plateau
level at around a mean PAP of 40 mmHg. Lankhaar et al[30] have
shown that compliance and resistance are inversely related and their
product, the resistance-compliance (RC) time constant, remains the
same in healthy individuals, PAH subjects, and even in PAH subjects
during the course of therapy. [31,32] Taken together, these
observations suggest that early changes in the pulmonary vascular
bed are better detected by changes in compliance rather than by
changes in PVR or PAP.
ThefindingsofourpresentstudyandthoseofLankhaaretalmay
also explain the apparent lack of effect of bosentan on measures of
arterial stiffness after 6-months of therapy. Although bosentan may
reduce PVR significantly via its vasodilator effect on the distal
microvasculature,PAHpatientswithadvanceddiseaseareoperating
at the flat part of the RC curve, and a significant reduction in
compliancewouldbeanunexpectedfindingevenifalargereduction
in resistance were to occur. In other words, patients with advanced
disease and a higher starting PVR may, with therapy, reduce their
PVRwithlittlechangeincompliance.Incontrast,patientswithearly
disease and a lower starting PVR may experience a proportional
improvement inboth PVR and compliance.
Study Limitations
Thefindingsofthepresentstudymustbeinterpretedinthecontext
ofthefollowinglimitations.Themainlimitationisthesmallnumber
Figure 2. Comparison of PA stiffness indices in control (n=12) and PAH subjects (n=20) at baseline. PAH subjects demonstrated
significantly greater stiffness in all measure indices; compliance (1.5060.11610
–2 mm
2/mmHg vs 4.4960.43610
–2 mm
2/mmHg, p,0.0001),
distensibility (0.3260.03%/mmHg vs 1.1860.13 %/mmHg, p,0.0001), elastic modulus (720664 mmHg vs 198619 mmHg, p,0.001), and stiffness
index b (15.061.4 vs 11.060.7, p=0.046). Data expressed as mean6SEM.
doi:10.1371/journal.pone.0033331.g002
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significantdifferencesinPAstiffnessfollowing6 monthsofbosentan
therapy,ourstudymayhavelackedsufficientpowertodetectsucha
difference.However,apost-hocanalysisindicatesthatourstudywas
powered to detect a relative change of 40% in PA compliance over
time.Wewereunabletostudythesamenumberofpulmonarylobesin
allsubjects,mainlyduetotechnicaldifficultiesinassessingallarterial
territories and the radiation exposure associated with prolonged
fluoroscopy times. In this study, the quality of the IVUS image was
inadequate for interpretation (.90u of the PA cross section was
unclear) in approximately 10% of the PAs studied. Nonetheless, the
majority of IVUS images were suitable for analysis and measure-
Figure 3. Individual data points of PA stiffness measurements before and after 6-months of therapy with bosentan in PAH subjects
(n=14). Bosentan therapy was associated with no significant changes in PA stiffness indices: compliance (1.5160.15610
–2 mm
2/mmHg at baseline
vs 1.5660.15610
–2 mm
2/mmHg at 6 months, p=0.86), distensibility (0.3160.04%/mmHg at baseline vs 0.3060.03%/mmHg at 6 months, p=0.92),
elastic modulus (763680 mmHg at baseline vs 756681 mmHg at 6 months, p=0.94), and stiffness index b (15.761.7 at baseline vs 18.161.3 at 6
months, p=0.198). Data expressed as mean6SEM.
doi:10.1371/journal.pone.0033331.g003
Figure 4. Pooled data points of control subjects (open circle) and PAH subjects (closed circle) showing the strong inverse
exponential associations between compliance and mean pulmonary artery pressure (left); and between distensibility and mean
pulmonary artery pressure (right). mPAP, mean pulmonary artery pressure.
doi:10.1371/journal.pone.0033331.g004
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modality,rightheartcatheterisationremainsanecessarycomponent
of the diagnostic evaluation of subjects with suspected PAH, and
IVUS canpotentially be performedin thesame setting.
Conclusions
We have demonstrated, using in vivo assessment with IVUS, that
the proximal elastic PA in patients with PAH undergo remodeling
accompanied by a marked increase in arterial stiffness. Thus,
pathophysiological changes of the proximal elastic PA play an
important contributing role to the overall RV afterload and the
development of RV failure in PAH. Despite the known vasodilator
effects of bosentan on the distal microvasculature, no change in
proximal arterial stiffness was observed following 6-months of
therapy. Current PAH-specific therapy may not exert significant
beneficial effect on arterial stiffness in subjects with advanced
disease, owing to the physiological phenomenon that changes
arterial stiffness occur early in PAH. This study further supports
the notion that evaluating changes in PA stiffness may have a role
in the early detection of pulmonary vascular disease.
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